219 related articles for article (PubMed ID: 35041929)
21. Phenotype prediction and characterization of 25 pharmacogenes in Thais from whole genome sequencing for clinical implementation.
Mauleekoonphairoj J; Chamnanphon M; Khongphatthanayothin A; Sutjaporn B; Wandee P; Poovorawan Y; Nademanee K; Pongpanich M; Chariyavilaskul P
Sci Rep; 2020 Nov; 10(1):18969. PubMed ID: 33144648
[TBL] [Abstract][Full Text] [Related]
22. A review of pharmacogenetic studies in the Bangladeshi population.
Mostaid MS; Aziz MA; Maisha JA; Islam MS; Maruf AA
Drug Metab Pers Ther; 2023 Jun; 38(2):123-131. PubMed ID: 36854045
[TBL] [Abstract][Full Text] [Related]
23. A comprehensive Thai pharmacogenomics database (TPGxD-1): Phenotype prediction and variants identification in 942 whole-genome sequencing data.
John S; Klumsathian S; Own-Eium P; Eu-Ahsunthornwattana J; Sura T; Dejsuphong D; Sritara P; Vathesatogkit P; Thongchompoo N; Thabthimthong W; Teerakulkittipong N; Chantratita W; Sukasem C
Clin Transl Sci; 2024 Jun; 17(6):e13830. PubMed ID: 38853370
[TBL] [Abstract][Full Text] [Related]
24. Role of CYP4F2, CYP2C19, and CYP1A2 polymorphisms on acenocoumarol pharmacogenomic algorithm accuracy improvement in the Greek population: need for sub-phenotype analysis.
Ragia G; Karantza IM; Kelli-Kota E; Kolovou V; Kolovou G; Konstantinides S; Maltezos E; Tavridou A; Tziakas D; Maitland-van der Zee AH; Manolopoulos VG
Drug Metab Pers Ther; 2017 Dec; 32(4):183-190. PubMed ID: 29252193
[TBL] [Abstract][Full Text] [Related]
25. Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention.
Dong OM; Wheeler SB; Cruden G; Lee CR; Voora D; Dusetzina SB; Wiltshire T
Value Health; 2020 Jan; 23(1):61-73. PubMed ID: 31952675
[TBL] [Abstract][Full Text] [Related]
26. Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy.
Pratt VM; Cavallari LH; Del Tredici AL; Gaedigk A; Hachad H; Ji Y; Kalman LV; Ly RC; Moyer AM; Scott SA; van Schaik RHN; Whirl-Carrillo M; Weck KE
J Mol Diagn; 2021 Sep; 23(9):1047-1064. PubMed ID: 34118403
[TBL] [Abstract][Full Text] [Related]
27. Development and Analytical Validation of a 29 Gene Clinical Pharmacogenetic Genotyping Panel: Multi-Ethnic Allele and Copy Number Variant Detection.
Scott SA; Scott ER; Seki Y; Chen AJ; Wallsten R; Owusu Obeng A; Botton MR; Cody N; Shi H; Zhao G; Brake P; Nicoletti P; Yang Y; Delio M; Shi L; Kornreich R; Schadt EE; Edelmann L
Clin Transl Sci; 2021 Jan; 14(1):204-213. PubMed ID: 32931151
[TBL] [Abstract][Full Text] [Related]
28. Identification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi population.
Goljan E; Abouelhoda M; ElKalioby MM; Jabaan A; Alghithi N; Meyer BF; Monies D
PLoS One; 2022; 17(1):e0263137. PubMed ID: 35089958
[TBL] [Abstract][Full Text] [Related]
29. Sequencing the CYP2D6 gene: from variant allele discovery to clinical pharmacogenetic testing.
Yang Y; Botton MR; Scott ER; Scott SA
Pharmacogenomics; 2017 May; 18(7):673-685. PubMed ID: 28470112
[TBL] [Abstract][Full Text] [Related]
30. Assessing the capability of massively parallel sequencing for opportunistic pharmacogenetic screening.
Ng D; Hong CS; Singh LN; Johnston JJ; Mullikin JC; Biesecker LG
Genet Med; 2017 Mar; 19(3):357-361. PubMed ID: 27537706
[TBL] [Abstract][Full Text] [Related]
31. Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population.
Skadrić I; Stojković O
Int J Legal Med; 2020 Mar; 134(2):433-439. PubMed ID: 31858263
[TBL] [Abstract][Full Text] [Related]
32. Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing.
Reizine NM; Danahey K; Truong TM; George D; House LK; Karrison TG; van Wijk XMR; Yeo KJ; Ratain MJ; O'Donnell PH
Cancer; 2022 Apr; 128(8):1649-1657. PubMed ID: 35090043
[TBL] [Abstract][Full Text] [Related]
33. Longitudinal exposure of English primary care patients to pharmacogenomic drugs: An analysis to inform design of pre-emptive pharmacogenomic testing.
Kimpton JE; Carey IM; Threapleton CJD; Robinson A; Harris T; Cook DG; DeWilde S; Baker EH
Br J Clin Pharmacol; 2019 Dec; 85(12):2734-2746. PubMed ID: 31454087
[TBL] [Abstract][Full Text] [Related]
34. Frequency of pharmacogenomic variants affecting efficacy and safety of anti-cancer drugs in a south Asian population from Sri Lanka.
Ranasinghe P; Sirisena N; Vishnukanthan T; Ariadurai JN; Thilakarathne S; Priyadarshani CDN; Bhagya Hendalage DP; Dissanayake VHW
BMC Med Genomics; 2024 May; 17(1):143. PubMed ID: 38789983
[TBL] [Abstract][Full Text] [Related]
35. A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.
Mizzi C; Dalabira E; Kumuthini J; Dzimiri N; Balogh I; Başak N; Böhm R; Borg J; Borgiani P; Bozina N; Bruckmueller H; Burzynska B; Carracedo A; Cascorbi I; Deltas C; Dolzan V; Fenech A; Grech G; Kasiulevicius V; Kádaši Ľ; Kučinskas V; Khusnutdinova E; Loukas YL; Macek M; Makukh H; Mathijssen R; Mitropoulos K; Mitropoulou C; Novelli G; Papantoni I; Pavlovic S; Saglio G; Setric J; Stojiljkovic M; Stubbs AP; Squassina A; Torres M; Turnovec M; van Schaik RH; Voskarides K; Wakil SM; Werk A; Del Zompo M; Zukic B; Katsila T; Lee MT; Motsinger-Rief A; Mc Leod HL; van der Spek PJ; Patrinos GP
PLoS One; 2016; 11(9):e0162866. PubMed ID: 27636550
[TBL] [Abstract][Full Text] [Related]
36. Potential Impact of Pharmacogenomic Single Nucleotide Variants in a Rural Caucasian Population.
Williams GR; Tsongalis GJ; Lewis LD; Barney RE; Cook LJ; Aaron Geno K; Nerenz RD
J Appl Lab Med; 2023 Mar; 8(2):251-263. PubMed ID: 36611001
[TBL] [Abstract][Full Text] [Related]
37. A Review of the Important Role of
Taylor C; Crosby I; Yip V; Maguire P; Pirmohamed M; Turner RM
Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33143137
[TBL] [Abstract][Full Text] [Related]
38. Considerations for rare variants in drug metabolism genes and the clinical implications.
Drögemöller BI; Wright GE; Warnich L
Expert Opin Drug Metab Toxicol; 2014 Jun; 10(6):873-84. PubMed ID: 24673405
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenetics of anxiety and depression in Alzheimer's disease.
Cacabelos R; Carril JC; Corzo L; Pego R; Cacabelos N; Alcaraz M; Muñiz A; Martínez-Iglesias O; Naidoo V
Pharmacogenomics; 2023 Jan; 24(1):27-57. PubMed ID: 36628952
[TBL] [Abstract][Full Text] [Related]
40. PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.
Hoffman JM; Haidar CE; Wilkinson MR; Crews KR; Baker DK; Kornegay NM; Yang W; Pui CH; Reiss UM; Gaur AH; Howard SC; Evans WE; Broeckel U; Relling MV
Am J Med Genet C Semin Med Genet; 2014 Mar; 166C(1):45-55. PubMed ID: 24619595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
